A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib [10]

Leukemia

Volumn 20, Issue 11, 2006, Pages 2057-2060

  Gruber, Franz X ^a   Hjorth Hansen, H ^b   Mikkola, I ^a   Stenke, L ^c   Johansen, T ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; COMPLEMENTARY DNA; DASATINIB; IMATINIB; MESSENGER RNA; UNCLASSIFIED DRUG;

AGED; AMINO ACID SUBSTITUTION; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CYTOGENETICS; DISEASE COURSE; DRUG RESISTANCE; DRUG RESPONSE; FEMALE; GENE DELETION; GENE SEQUENCE; HUMAN; LETTER; MALE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PHILADELPHIA 1 CHROMOSOME; POINT MUTATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS;

EID: 33750344192     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404400     Document Type: Letter

References (8)

1. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
2. Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M. New tyrosine kinase inhibitors in chronic myeloid leukemia. Haematologica 2005; 90: 534-541.
3. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117-125.
4. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003; 17: 2318-2357.
5. Gruber FX, Lamark T, Anonli A, Sovershaev MA, Olsen M, Gedde-Dahl T et al. Selecting and deselecting imatinib-resistant clones: Observations made by longitudinal, quantitative monitoring of mutated BCR-ABL. Leukemia 2005; 19: 2159-2165.
6. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190-2196.
7. Nalla VK, Rogan PK. Automated splicing mutation analysis by information theory. Hum Mutat 2005; 25: 334-342.
8. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289: 1938-1942.